이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Processa Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Processa Pharmaceuticals의 수입은 연평균 -26.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업의 수입은 연간 감소했습니다(0.4%).

주요 정보

-26.4%

수익 성장률

-1.9%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	n/a
자기자본 수익률	-110.6%
순이익	n/a
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20

수익 및 비용 분석

Processa Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:PCSA 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
31 Mar 24	-10	4	6
31 Dec 23	-11	6	6
30 Sep 23	-22	7	8
30 Jun 23	-26	9	10
31 Mar 23	-28	10	11
31 Dec 22	-27	9	11
30 Sep 22	-18	7	10
30 Jun 22	-15	6	9
31 Mar 22	-13	5	7
31 Dec 21	-11	5	7
30 Sep 21	-23	5	7
30 Jun 21	-23	4	5
31 Mar 21	-20	3	4
31 Dec 20	-19	3	3
30 Sep 20	-6	2	2
30 Jun 20	-4	2	2
31 Mar 20	-4	2	2
31 Dec 19	-4	2	2
30 Sep 19	-3	1	2
30 Jun 19	-3	1	2
31 Mar 19	-3	1	3
31 Dec 18	-4	1	3
30 Sep 18	-4	1	3
30 Jun 18	-4	1	3
31 Mar 18	-3	1	2
31 Dec 17	-2	1	1
31 Dec 16	-2	0	2

양질의 수익: PCSA 은(는) 현재 수익성이 없습니다.

이익 마진 증가: PCSA 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: PCSA 은(는) 수익성이 없으며 지난 5년 동안 연간 26.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 PCSA 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: PCSA 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 19.9% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: PCSA 현재 수익성이 없기 때문에 마이너스 자본 수익률( -110.61% )을 갖습니다.

Processa Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2024

Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research

Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial

New major risk - Shareholder dilution

Co-Founder recently bought US$51k worth of stock

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.99989 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14.35 million.

Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals, Inc. Appoints George Ng as Chief Executive Officer

New major risk - Share price stability

New major risk - Market cap size

Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Positive Gastric Emptying Results from its Pcs12852 Phase 2A Trial in Patients

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals, Inc. Provides Update on Enrollment Across All Clinical Programs

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Board Changes

Processa Pharmaceuticals, Inc. Elects Khoso Baluch as Director

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc., Annual General Meeting, Jul 11, 2022

Price target decreased to US$15.00

Processa Pharmaceuticals, Inc. Doses First Patient in Amended Phase 1B Protocol for Pcs6422 Combined with Capecitabine

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

Co-Founder recently bought US$77k worth of stock

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Processa Pharmaceuticals, Inc. Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals, Inc. announced that it has received $10.238773 million in funding

New 90-day high: US$10.89

Processa Pharmaceuticals, Inc. announced that it expects to receive $10.238773 million in funding

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Processa Pharmaceuticals, Inc. Announces Executive Changes

Processa Pharmaceuticals, Inc. Appoints R. Michael Floyd as Chief Operating Officer

Co-Founder recently bought US$125k worth of stock

Processa Pharmaceuticals, Inc. has completed an IPO in the amount of $19.2 million.

New 90-day low: US$3.95

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기